Publications by authors named "Harry D Bear"

Claim this Profile
T
Targeting Bcl-xL to eliminate chemotherapy-induced tumor dormancy and prevent breast cancer metastasis.
Kinjal Gupta, Nicholas Koelsch, Victoria Neely, Laura Graham, Harry D Bear

Br J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allostatic Load and Racial and Rural Disparities in Breast Cancer Survival.
Yufan Guan, Roger T Anderson, Supraja Gururaj, Wendy F Cohn, Philip I-Fon Chow, Harry D Bear

JAMA Netw Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Shen et al. Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival. 2025, , 1502.
Jie Shen, Yufan Guan, Supraja Gururaj, Kai Zhang, Qian Song, Harry D Bear

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neighborhood Disadvantage, Built Environment, and Breast Cancer Outcomes: Disparities in Tumor Aggressiveness and Survival.
Jie Shen, Yufan Guan, Supraja Gururaj, Kai Zhang, Qian Song, Harry D Bear

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.
Carsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, Karsten Weber, Miguel Martin, Harry D Bear

Cancer Cell· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy.
Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery.
Patricia A Ganz, Reena S Cecchini, Julia R White, Frank A Vicini, Douglas W Arthur, Harry D Bear

J Natl Cancer Inst· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
Carolyn Haynes, Laura Graham, Harry D Bear

Methods Cell Biol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unexpected Clinical Outcome for Myxoinflammatory Fibroblastic Sarcoma, When Should They Be Considered High Grade?
Brian K Sparkman, Tuong Vi V Nguyen, Steven Christopher Smith, Harry D Bear

J Investig Med High Impact Case Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer, Catherine A Azar, Harry D Bear

Breast Cancer Res Treat· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
Katya Galactionova, Sibylle Loibl, Paola Salari, Frederik Marmé, Miguel Martin, Harry D Bear

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neighborhood disadvantage and biological aging biomarkers among breast cancer patients.
Jie Shen, Bernard F Fuemmeler, Vanessa B Sheppard, Harry D Bear, Renduo Song

Sci Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
Amy H Tang, Richard A Hoefer, Mary L Guye, Harry D Bear

Cancer Drug Resist· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
Marion T van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O'Shaughnessy, Miguel Martin, Harry D Bear

Eur J Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
Zheng Liu, Chunqing Guo, Swadesh K Das, Xiaofei Yu, Anjan K Pradhan, Harry D Bear

Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity.
Xiaofei Yu, Wenjie Liu, Shixian Chen, Xueqian Cheng, Patrick A Paez, Harry D Bear

J Immunother Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets.
Hussein F Aqbi, Cara Coleman, Melika Zarei, Saeed H Manjili, Laura Graham, Harry D Bear

Breast Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gagan K Gupta, Amber L Collier, Dasom Lee, Richard A Hoefer, Vasilena Zheleva, Harry D Bear

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Andrea J Luker, Laura J Graham, Timothy M Smith, Carmen Camarena, Matt P Zellner, Harry D Bear

BMC Immunol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
Frank A Vicini, Reena S Cecchini, Julia R White, Douglas W Arthur, Thomas B Julian, Harry D Bear

Lancet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
If we build it they will come: targeting the immune response to breast cancer.
Margaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, Harry D Bear, Sangeetha Prabhakaran

NPJ Breast Cancer· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters.
Harry D Bear, Kandace P McGuire

Ann Surg Oncol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gr1 CD11b MHCII myeloid cells boost T cell anti-tumor efficacy.
Kyle K Payne, Hussein F Aqbi, Savannah E Butler, Laura Graham, Rebecca C Keim, Harry D Bear

J Leukoc Biol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generosity and Duration of Medicaid Expansion Waivers and Access to Care.
Wafa W Tarazi, Cathy J Bradley, David W Harless, Harry D Bear, Lindsay M Sabik

Am J Prev Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Re: Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):917-923.
Harry D Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani

J Surg Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis